NHS England South - PGD Page
Patient Group Directions (PGDs) are written instructions for the supply or administration of medicines to groups of patients who may not be individually identified before presentation for treatment. NHS PGDs must only be used as part of a commissioned NHS service.
PGD’s are now being posted on the NHS England South website link to page
One new PGD has been authorised for a range of registered healthcare professionals to use. 20 August 2021
- Diphtheria, tetanus, pertussis, polio, Haemophilus influenzae and hepatitis B vaccine (DTaP/IPV/Hib/HepB) PGD V03.00
for the administration of diphtheria, tetanus, pertussis, polio, Haemophilus influenzae and hepatitis B vaccine to individuals from 6 weeks (routinely 8 weeks) to under 10 years of age in accordance with the national immunisation programme
Changes from V2.00:
- include minor rewording, layout and formatting changes for clarity and consistency with other PHE PGDs and updated references
- addition of Vaxelis® suspension
- addition of stability data
Three new PGDs have been authorised for a range of registered healthcare professionals to use - 9 August 2021
- Inactivated influenza IM vaccine PGD V09.00
for the administration of inactivated influenza vaccine to individuals in accordance with the national influenza immunisation programme.
Changes from V8.00:
- includes eligible cohorts for the 2021/22 season
- includes the inactivated influenza vaccines for the 2021/22 season
- includes minor rewording, layout and formatting changes for clarity and consistency with other PHE PGDs
- Live attenuated influenza intranasal vaccine (LAIV) PGD V10.00
for the supply and administration, or supply only, of live attenuated influenza vaccine (LAIV) nasal spray suspension (Fluenz Tetra) to children and adolescents from 2 years to under 18 years of age in accordance with the national flu immunisation programme.
Changes from V9.00:
- includes eligible cohorts for the 2021/22 season
- HPV vaccine PGD V04.00
for the administration of human papillomavirus vaccine (HPV) to individuals from 12 years of age or from school year 8 in accordance with the national immunisation programme
Changes from V03.00:
- includes the 9-valent vaccine (Gardasil® 9)
- includes minor rewording, layout and formatting changes for clarity and consistency with other PHE PGD templates
Three new PGDs have been authorised for a range of registered healthcare professionals to use:
- MenACWY Risk Groups PGD V03.00 – valid from 1 March 2021
For the administration of meningococcal group A, C, W, and Y vaccine (MenACWY) to individuals with an underlying medical condition which puts them at increased risk from Neisseria meningitidis.
Updates:
- express dose interval in weeks and remove specific reference to Hib/MenC in line with Chapter 7 of the Green Book
- include minor rewording, layout and formatting changes for clarity and consistency with other PHE PGD templates
- MenB Risk Groups PGD V03.00 – valid from 1 March 2021
For the administration of meningococcal group B vaccine (MenB) to individuals, from 2 years of age, with an underlying medical condition which puts them at increased risk from Neisseria meningitidis group B.
Updates:
- off-label and dose section to reflect changes in the summary of product characteristics, which now includes administration at not less than one-month interval from 2 years of age
- exclude those who have completed a course of 4CMenB
- include a caution relating to immunosuppressed individuals
- update adverse drug reactions section
- clarify supplies section
- include rewording, layout and formatting changes for clarity and consistency with other PHE PGD templates
- MenB PGD V05.00 – valid from 1 March 2021
For the administration of meningococcal group B vaccine (MenB) to individuals from 8 weeks of age eligible for the national routine immunisation programme and to individuals for the prevention of secondary cases of meningococcal group B disease.
Updates:
- update off-label section because SPC now includes administration of 2+1 schedule starting at 2 months
- update adverse drug reactions section
- include a caution relating to immunosuppressed individuals
- update adverse drug reactions section
- include rewording, layout and formatting changes for clarity and consistency with other PHE PGD templates
